Maui, Hawaii - Preliminary results from an open-label study suggest PUVA-bexarotene is a safe and effective combination regimen for the treatment of early cutaneous T-cell lymphoma (CTCL), Joan Guitart, M.D., said at the annual Hawaii Dermatology Seminar, sponsored by the Skin Disease Education Foundation.